Literature DB >> 19381107

When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal.

Alberto Zanchetti1, Guido Grassi, Giuseppe Mancia.   

Abstract

The evidence for two recommendations of all major guidelines on hypertension is critically discussed. The first recommendation is that of initiating antihypertensive drug treatment when systolic blood pressure is at least 140 or diastolic blood pressure at least 90 mmHg in patients with grade 1 hypertension and low or moderate total cardiovascular risk, and even when blood pressure is in the high normal range in patients with diabetes and previous cardiovascular disease. The second recommendation is that of achieving systolic blood pressure levels below 140 mmHg in all hypertensive patients, including the elderly, and values below 130 mmHg in patients having diabetes and high/very-high-risk patients. Critical analyses of the results of available trials show that the evidence is scanty for both recommendations. Nonetheless, they can be accepted as prudent statements, as antihypertensive agents are very well tolerated and lowering systolic blood pressure below 130 mmHg appears well tolerated. However, wisdom should not be taken for evidence, and simple trials should be designed to look for more solid evidence in favour of current recommendations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381107     DOI: 10.1097/HJH.0b013e32832aa6b5

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  57 in total

Review 1.  Gene silencing in DNA damage repair.

Authors:  H Soejima; K Joh; T Mukai
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

Review 2.  Systolic pressure, diastolic pressure, or pulse pressure as a cardiovascular risk factor in renal disease.

Authors:  José A García-Donaire; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

3.  [Therapeutic targets in arterial hypertension and diabetes mellitus. Can medical prevention be harmful?].

Authors:  C Chatzikyrkou; H Haller; J Menne
Journal:  Internist (Berl)       Date:  2012-07       Impact factor: 0.743

4.  Current status of aggressive blood pressure control.

Authors:  Steven G Chrysant
Journal:  World J Cardiol       Date:  2011-03-26

5.  Can treating the diastolic blood pressure below a certain value increase cardiovascular risk?

Authors:  Norman M Kaplan
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

6.  [New ESH/ESC guidelines on arterial hypertension : what is new and what indications remain for renal denervation?].

Authors:  P Groha; S Kufner; I Ott; H Schunkert
Journal:  Herz       Date:  2014-12       Impact factor: 1.443

7.  Hypertension: Lower or higher blood-pressure targets for high-risk patients?

Authors:  Alberto Zanchetti
Journal:  Nat Rev Cardiol       Date:  2016-10-06       Impact factor: 32.419

Review 8.  New Hypertension Guidelines: Progression or a Step Backwards in Hypertension?

Authors:  Markus van der Giet; Markus Tölle
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 9.  Prevention of coronary artery disease: recent advances in the management of hypertension.

Authors:  Chiara Recarti; Thomas Unger
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

10.  IL-24 gene polymorphisms are associated with cardiometabolic parameters and cardiovascular risk factors but not with premature coronary artery disease: the genetics of atherosclerotic disease Mexican study.

Authors:  Gilberto Vargas-Alarcón; Carlos Posadas-Romero; Teresa Villarreal-Molina; Edith Alvarez-León; Javier Angeles-Martinez; Rosalinda Posadas-Sanchez; Irma Monroy-Muñoz; Sergio Luna-Fuentes; Carmen González-Salazar; Julian Ramirez-Bello; Guillermo Cardoso-Saldaña; Aida Medina-Urrutia; Eric Kimura-Hayama
Journal:  J Interferon Cytokine Res       Date:  2014-02-19       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.